Physicians' Academy for Cardiovascular Education

Can LDL go too low? Lessons from 25 years of cholesterol lowering

Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

Diverse study data confirm the rationale of intensive lipid-lowering

Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

First time CV reduction is achieved with CETP inhibition

Aug. 29, 2017

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

Aug. 28, 2017

Natural randomisation shows that mode of LDL-lowering determines CV benefit

Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

Aug. 28, 2017

UK: Clinical Dialogues: Lipids & Diabetes 2017

July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

Can LDL go too low? Lessons from 25 years of cholesterol lowering

Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Time to better counteract the anti-statin lobby, to prevent unnecessary harm to patients

Jan. 4, 2018 - news

Following a TV program on the French-German public network ARTE that denied the proven link between cholesterol levels and CVD, the potential effects of such disinformation are considered.

CETP is associated with atherosclerosis only in specific subpopulations

Dec. 5, 2017 - Christen T et al. - J Clin Lipidol. 2017

Mendelian randomisation suggests that CETP is not causally related to atherosclerosis in the general population, but only in men with normal glucose, HDL, and TG levels, and in women with ¬¬high CV risk or abnormal fasting glucose.

Statin therapy associated with a lower risk of Parkinson’s Disease

Nov. 27, 2017 - Poly TN et al. - Neuroepidemiology 2017

In a meta-analysis of 13 observational studies, statin use was associated with a modest reduction in the risk of developing Parkinson’s Disease compared with not using statins.

PCSK9 LOF variants and low LDL-c levels not associated with neurocognitive impairment

Nov. 24, 2017 - Mefford MT et al. - Circulation 2017

Data of large prospective cohort of African-Americans suggest that life-long exposure to low PCSK9 levels and the resulting low levels of LDL-C do not have major effects on neurocognitive outcomes.

Effect CETP inhibitor similar in vascular patients with or without diabetes

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Martin Landray (University of Oxford, Oxford, United Kingdom)

Nov. 21, 2017 - news

AHA 2017 A REVEAL-analysis shows that diabetes status does not affect the effect of anacetrapib on serious coronary events, and that anacetrapib slightly lowers the risk of new onset diabetes.

PCSK9 inhibitor lowers CV risk in peripheral artery disease and in high-risk patients with previous MI

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Marc Bonaca and Marc Sabatine (Brigham and Women’s Hospital, Boston, MA, USA)

Nov. 21, 2017 - news

AHA 2017 New FOURIER analyses show benefit of treatment with evolocumab both in patiënts with PAD, and clinical factors in high-risk post-MI patients can predict extra high risk.

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

AHA 2017 - Anaheim, CA, USA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS
Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

Patients with severe hypertriglyceridemia benefit from omega-3 carboxylic acids 2 g/day

Nov. 9, 2017 - Stroes ESG, et al. - J Clin Lipidol 2017

Patients with SHTG treated with OM3-CA 2 g daily had a statistically significant reduction in TG and non-HDL-c concentrations compared with those treated with olive oil 2 g daily.

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017
Lecture by Peter Sever, MD held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.